Table Graph
      published meta-analysis   sensitivity analysis   studies

control in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25] 0.31[0.07; 1.25]Darazam (COVIFERON Interferon beta-1a), 202110%40NAnot evaluable clinical improvementdetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] 2.36[1.09; 5.12]Darazam (COVIFERON Interferon beta-1a), 202110%40NAnot evaluable clinical improvement (time to event analysis only)detailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] 2.36[1.09; 5.12]Darazam (COVIFERON Interferon beta-1a), 202110%40NAnot evaluable mechanical ventilationdetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67] 1.00[0.27; 3.67]Darazam (COVIFERON Interferon beta-1a), 202110%40NAnot evaluable ICU admissiondetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71] 1.00[0.21; 4.71]Darazam (COVIFERON Interferon beta-1a), 202110%40NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-18 08:59 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 649,650,589,651,968 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons